ECSP13012710A - Método de tratamiento con inhibidores selectivos de bcl-2 - Google Patents

Método de tratamiento con inhibidores selectivos de bcl-2

Info

Publication number
ECSP13012710A
ECSP13012710A ECSP13012710A ECSP13012710A EC SP13012710 A ECSP13012710 A EC SP13012710A EC SP13012710 A ECSP13012710 A EC SP13012710A EC SP13012710 A ECSP13012710 A EC SP13012710A
Authority
EC
Ecuador
Prior art keywords
bcl
treatment method
selective inhibitors
activity
treatment
Prior art date
Application number
Other languages
English (en)
Inventor
Tariq Ghayur
Steven W Elmore
Andrew J Souers
Li Chun Wang
Stuart J Perper
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45218888&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012710(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of ECSP13012710A publication Critical patent/ECSP13012710A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos de tratamiento de lupus eritematoso sistémico, nefritis lúpica o síndrome de Sjogren con compuestos que inhiben selectivamente la actividad de las proteínas anti apoptóticas Bcl 2. Específicamente, la presente invención está dirigida al tratamiento con compuestos que inhiben selectivamente la actividad de proteínas Bcl-2, con una menor afinidad por la inhibición de la actividad de otras proteínas de la familia Bcl-2, incluyendo Bcl- xL.
ECSP13012710 2010-11-23 2013-06-21 Método de tratamiento con inhibidores selectivos de bcl-2 ECSP13012710A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41668910P 2010-11-23 2010-11-23

Publications (1)

Publication Number Publication Date
ECSP13012710A true ECSP13012710A (es) 2013-08-30

Family

ID=45218888

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012710 ECSP13012710A (es) 2010-11-23 2013-06-21 Método de tratamiento con inhibidores selectivos de bcl-2

Country Status (36)

Country Link
US (5) US20120129853A1 (es)
EP (2) EP2642999B1 (es)
JP (2) JP5876067B2 (es)
KR (3) KR20180030257A (es)
CN (2) CN105664164B (es)
AR (1) AR083946A1 (es)
AU (2) AU2011332000B2 (es)
BR (1) BR112013012854B1 (es)
CA (1) CA2820618C (es)
CL (1) CL2013001458A1 (es)
CR (1) CR20130268A (es)
CY (1) CY1118442T1 (es)
DK (1) DK2642999T3 (es)
DO (1) DOP2017000056A (es)
EC (1) ECSP13012710A (es)
ES (2) ES2603129T3 (es)
GT (1) GT201300136A (es)
HR (1) HRP20161762T1 (es)
HU (1) HUE031267T2 (es)
IL (2) IL226490A (es)
LT (1) LT2642999T (es)
MX (2) MX346201B (es)
MY (2) MY191300A (es)
NZ (2) NZ610746A (es)
PH (2) PH12013501006A1 (es)
PL (1) PL2642999T3 (es)
PT (1) PT2642999T (es)
RS (1) RS55545B1 (es)
RU (1) RU2593231C2 (es)
SG (2) SG190399A1 (es)
SI (1) SI2642999T1 (es)
TW (2) TWI535701B (es)
UA (2) UA113157C2 (es)
UY (1) UY33746A (es)
WO (1) WO2012071374A1 (es)
ZA (1) ZA201303589B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
ES2603129T3 (es) 2010-11-23 2017-02-23 Abbvie Ireland Unlimited Company Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2
MX2014007093A (es) 2011-12-13 2014-10-13 Buck Inst For Res On Aging Metodos para mejorar terapias medicas.
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
HK1212240A1 (en) 2012-09-07 2016-06-10 吉宁特有限公司 Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
WO2014043223A1 (en) * 2012-09-11 2014-03-20 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
CN105164128B (zh) 2013-03-13 2017-12-12 艾伯维公司 制备细胞凋亡诱导剂的方法
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
IL286427B2 (en) 2014-01-28 2024-08-01 Mayo Found Medical Education & Res Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
EP3139942B1 (en) * 2014-05-05 2019-12-18 Bioventures, Llc COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
PL3179991T3 (pl) 2014-08-11 2022-02-14 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
BR112018002550A2 (en) 2015-08-10 2018-09-18 Dana-Farber Cancer Institute, Inc. inhibitor resistance mechanism
KR102124715B1 (ko) 2015-11-03 2020-06-18 제넨테크, 인크. 암의 치료를 위한 bcl-2 억제제 및 mek 억제제의 조합물
CN109152933B (zh) * 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
US10829488B2 (en) 2016-08-05 2020-11-10 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
CN110759908B (zh) * 2017-06-26 2021-03-12 深圳市塔吉瑞生物医药有限公司 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
US11480568B2 (en) * 2017-09-28 2022-10-25 Yeda Research And Development Co. Ltd. Diagnosis of autoimmune diseases
KR20200108301A (ko) 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
ES3041854T3 (en) 2018-01-22 2025-11-17 Bioventures Llc Bcl-2 proteins degraders for cancer treatment
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
US20190328729A1 (en) 2018-04-26 2019-10-31 Emory University Uses of Bcl-2 Antagonists for Treating Cancer and Diagnostics Related Thereto
BR112020018978A2 (pt) 2018-07-31 2021-03-02 Ascentage Pharma (Suzhou) Co., Ltd. produto de combinação que compreende um inibidor de bcl-2 e um inibidor de mdm2 e uso dos ditos inibidores na prevenção e/ou tratamento de câncer
US11554127B2 (en) 2018-07-31 2023-01-17 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
CA3095699A1 (en) 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
CN114522167A (zh) 2018-07-31 2022-05-24 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
SG11202101955SA (en) 2018-09-18 2021-03-30 Signalchem Lifesciences Corp Combination therapy for treating blood cancer
AU2019372640B2 (en) 2018-10-29 2022-08-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor
US12319689B2 (en) 2019-05-24 2025-06-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor
CN112707900B (zh) * 2019-10-24 2022-06-10 上海科技大学 蛋白降解剂及其在疾病治疗中的应用
CN113444078B (zh) * 2020-03-25 2023-07-07 中国科学院上海有机化学研究所 抗凋亡蛋白Bcl-2抑制剂及其制备方法和应用
CN115916822A (zh) 2020-04-24 2023-04-04 基因泰克公司 使用抗CD79b免疫缀合物的方法
US12545674B2 (en) 2020-04-29 2026-02-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal of trifluoromethyl/chloro disubstituted sulfonamide selective BCL-2 inhibitor
US20230301989A1 (en) * 2020-08-21 2023-09-28 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating systemic lupus erythematosus
MX2023011000A (es) * 2021-03-19 2023-09-28 Eil Therapeutics Inc Compuestos que contienen ((3-nitrofenilo)sulfonilo)acetamida como inhibidores bcl-2.
WO2022216942A1 (en) 2021-04-07 2022-10-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
US20240287110A1 (en) 2021-06-04 2024-08-29 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Phosphate of trifluoromethyl-substituted sulfonamide compound
IT202100025976A1 (it) 2021-10-06 2023-04-06 Univ Degli Studi Di Perugia Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1)
WO2024102890A2 (en) * 2022-11-11 2024-05-16 The Board Of Regents Of The University Of Texas System Amino acid-benzoic acid oligomers and methods of use thereof for treating cancer

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2128208A (en) 1937-02-27 1938-08-23 Du Pont Alkoxy derivatives of methacrylic acid esters and method of producing them
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
DE69631347T2 (de) 1995-09-15 2004-10-07 Upjohn Co Aminoaryl oxazolidinone n-oxide
MX336813B (es) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
HUP0104634A3 (en) 1998-07-06 2002-11-28 Bristol Myers Squibb Co Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
CA2338328A1 (en) * 1998-07-21 2000-02-03 Thomas Jefferson University Small molecule inhibitors of bcl-2 proteins
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
US6787534B2 (en) 1999-12-28 2004-09-07 Eisai Co., Ltd. Sulfonamide-containing heterocyclic compounds
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7183320B2 (en) 2001-06-06 2007-02-27 Eli Lilly And Company Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US20090247613A1 (en) 2002-02-20 2009-10-01 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
KR20040086452A (ko) 2002-02-26 2004-10-08 아스트라제네카 아베 항암 화합물 ｚｄ1839의 신규한 결정질 형태
BRPI0307786B8 (pt) 2002-02-26 2021-05-25 Astrazeneca Ab composição farmacêutica, método para preparar a mesma, métodos para inibir a taxa de precipitação do agente da solução no trato gi, e para reduzir variabilidade inter-pacientes no que se refere à biodisponibilidade e/ou concentrações plásmáticas do agente, e, uso de um celulose éter solúvel em água ou de um éster de um celulose éter solúvel em água
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
JO2479B1 (en) 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
WO2005024636A1 (ja) 2003-09-04 2005-03-17 Hitachi Ulsi Systems Co., Ltd. 半導体装置
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
ATE395905T1 (de) 2004-08-27 2008-06-15 Bayer Pharmaceuticals Corp Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
RU2387653C2 (ru) 2005-05-16 2010-04-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназ
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US20070202077A1 (en) 2005-12-02 2007-08-30 Brodsky Robert A Use of High-Dose Oxazaphosphorine Drugs for Treating Immune Disorders
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
JP5277168B2 (ja) 2006-09-05 2013-08-28 アボット・ラボラトリーズ 血小板過剰を治療するｂｃｌインヒビター
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
KR101222412B1 (ko) 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
WO2008124878A1 (en) 2007-04-13 2008-10-23 Cryptopharma Pty Ltd Non-steroidal compounds
AU2008242703B2 (en) 2007-04-19 2011-08-18 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
EP2193127A4 (en) * 2007-09-27 2011-09-14 Inst Medical W & E Hall BENZOTHIAZOLE COMPOUNDS
US20110123482A1 (en) * 2007-10-01 2011-05-26 The Johns Hopkins University Methods of Treating Neurological Autoimmune Disorders with Cyclophosphamide
EP2197957A1 (en) 2007-10-01 2010-06-23 Arkema, Inc. Blends of biodegradable polymers and acrylic copolymers
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
EP2205088B1 (en) * 2007-10-19 2018-02-21 Burnham Institute for Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
EP2217548A1 (en) 2007-10-26 2010-08-18 Concert Pharmaceuticals Inc. Deuterated darunavir
CA2705294C (en) 2007-11-16 2016-05-17 Abbott Laboratories Methods of treating arthritis by the administration of substituted benzenesulfonamides
EP2219651A1 (en) 2007-12-06 2010-08-25 Abbott Laboratories Oral compositions of abt-263 for treating cancer
CN101481363B (zh) * 2008-01-10 2011-05-04 江苏豪森药业股份有限公司 一种制备瑞格列奈的方法
TWI478937B (zh) 2008-01-15 2015-04-01 Abbvie Inc 改良之哺乳動物表現載體及其用途
JP2011517698A (ja) * 2008-04-15 2011-06-16 バーンハム インスティテュート フォー メディカル リサーチ 抗アポトーシスタンパク質の阻害剤
CA2737400C (en) 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
DK2376480T3 (en) * 2008-12-05 2016-09-12 Abbvie Inc Sulfonamide derivatives AS BCL-2-selective apoptosis inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) * 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US20110245156A1 (en) 2008-12-09 2011-10-06 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
WO2010072734A2 (en) 2008-12-23 2010-07-01 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
CA2747835A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010083442A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010138588A2 (en) 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
ES2603129T3 (es) * 2010-11-23 2017-02-23 Abbvie Ireland Unlimited Company Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose

Also Published As

Publication number Publication date
CN103402521A (zh) 2013-11-20
ZA201303589B (en) 2014-07-30
US9872861B2 (en) 2018-01-23
MY191300A (en) 2022-06-14
TW201630885A (zh) 2016-09-01
BR112013012854A2 (pt) 2016-08-23
CA2820618C (en) 2020-04-21
SI2642999T1 (sl) 2017-01-31
GT201300136A (es) 2014-08-05
HUE031267T2 (en) 2017-06-28
NZ610746A (en) 2015-06-26
TWI535701B (zh) 2016-06-01
KR20190109590A (ko) 2019-09-25
US20120129853A1 (en) 2012-05-24
KR20140004659A (ko) 2014-01-13
IL226490A0 (en) 2013-07-31
WO2012071374A1 (en) 2012-05-31
EP3028702B1 (en) 2018-09-12
MX377232B (es) 2025-03-04
BR112013012854A8 (pt) 2018-01-16
CA2820618A1 (en) 2012-05-31
IL251845B (en) 2019-06-30
JP2013543896A (ja) 2013-12-09
IL251845A0 (en) 2017-06-29
US9345702B2 (en) 2016-05-24
EP2642999A1 (en) 2013-10-02
MX346201B (es) 2017-03-09
CN105664164A (zh) 2016-06-15
AU2016204396A1 (en) 2016-07-14
PL2642999T3 (pl) 2017-04-28
LT2642999T (lt) 2017-01-25
ES2603129T3 (es) 2017-02-23
TW201302705A (zh) 2013-01-16
AU2011332000B2 (en) 2016-07-07
US20150150870A1 (en) 2015-06-04
CL2013001458A1 (es) 2013-10-04
MX2013005849A (es) 2013-07-05
UA113157C2 (xx) 2016-12-26
JP6215368B2 (ja) 2017-10-18
BR112013012854B1 (pt) 2019-08-06
UA119150C2 (uk) 2019-05-10
ES2701603T3 (es) 2019-02-25
MY165884A (en) 2018-05-18
SG190399A1 (en) 2013-06-28
EP3028702A1 (en) 2016-06-08
NZ708508A (en) 2016-06-24
KR101841084B1 (ko) 2018-03-23
US20160235760A1 (en) 2016-08-18
DK2642999T3 (en) 2017-01-09
HRP20161762T1 (hr) 2017-02-24
PH12016500939B1 (en) 2018-11-09
IL226490A (en) 2017-05-29
CR20130268A (es) 2013-10-17
CN105664164B (zh) 2020-05-05
TWI620736B (zh) 2018-04-11
JP2016117744A (ja) 2016-06-30
UY33746A (es) 2012-06-29
AU2011332000A1 (en) 2013-06-06
PH12013501006A1 (en) 2022-03-30
SG10201509631SA (en) 2015-12-30
CN103402521B (zh) 2016-01-20
CY1118442T1 (el) 2017-06-28
AR083946A1 (es) 2013-04-10
DOP2017000056A (es) 2017-03-31
RU2593231C2 (ru) 2016-08-10
EP2642999B1 (en) 2016-09-28
PT2642999T (pt) 2017-01-05
RS55545B1 (sr) 2017-05-31
RU2013128544A (ru) 2014-12-27
JP5876067B2 (ja) 2016-03-02
PH12016500939A1 (en) 2017-06-14
US20180369250A1 (en) 2018-12-27
US20200222413A1 (en) 2020-07-16
KR20180030257A (ko) 2018-03-21
AU2016204396B2 (en) 2017-10-26
US20170232000A9 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
DOP2017000056A (es) Métodos de tratamiento con inhibidores selectivos de bcl-2
IL268856A (en) Methods for purification of messenger rna
EA201391329A1 (ru) Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3)
CY1120079T1 (el) Υδατικη συνθεση που περιεχει βρωμεξινη
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
AR077016A1 (es) Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales
UY32680A (es) AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CÁNCER Y ENFERMEDADES INMUNES
MX393993B (es) Inhibidores de bromodominio
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
ECSP12012017A (es) DERIVADOS DE SULFONAMIDA COMO AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CÁNCER Y ENFERMEDADES INMUNES
MA35660B1 (fr) Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile
JO3407B1 (ar) مركبات رباعي هيدرو بيرازولو بيريميدين
BR112012012529A2 (pt) composto indol e seu uso farmacêutico
BR112014009866A2 (pt) formulações de anticorpos e métodos
WO2012065102A3 (en) S-t-butyl protected cysteine di-peptide analogs and related compounds
BR112014011254A2 (pt) 2-tiopirimidinonas
ATE533774T1 (de) Neuartige nukleosidanaloge zur behandlung von virusinfektionen
BRPI1010911A2 (pt) "anticorpos ou fragmentos destes direcionados contra um epitopo de staphylococcus aureus"
ATE551319T1 (de) Sgk1-inhibitoren zur prophylaxe und/oder therapie von viralen erkrankungen und/oder karzinomen
MA39126A3 (fr) Synthèse d'enantiomère de progestérone et d'intermédiaires de celui-ci
FR2905600B1 (fr) Traitement des vertiges par l'acetyl-l-leucine.
EA201291371A1 (ru) Ингибитор репликации геминивируса
EP3472621A4 (en) Methods of electrospray ionization of glycans modified with amphipathic, strongly basic moieties
UA111951C2 (uk) Заміщені аналоги нуклеотидів
TH152979A (th) "ตัวกรอง"